austlii:cth/ARTA/2026/446
General information, not legal advice.
ARTA
2026-03-27
Original judgment source is linked above.
(1) For the purposes of specifying, in a statement of participant supports, the general supports that will be provided, and the reasonable and necessary supports that will be funded, the CEO must be satisfied of all of the following in relation to the funding or provision of each such support:
(aa) the support is necessary to address needs of the participant arising from an impairment in relation to which the participant meets the disability requirements (see section 24) or the early intervention requirements (see section 25);
(a) the support will assist the participant to pursue the goals, objectives and aspirations included in the participant's statement of goals and aspirations;
(b) the support will assist the participant to undertake activities, so as to facilitate the participant's social and economic participation;
(c) the support represents value for money in that the costs of the support are reasonable, relative to both the benefits achieved and the cost of alternative support;
(d) the support will be, or is likely to be, effective and beneficial for the participant, having regard to current good practice;
(e) the funding or provision of the support takes account of what it is reasonable to expect families, carers, informal networks and the community to provide;
(f) the support is an NDIS support for the participant.
(a) the time at which the disability requirements or the early intervention requirements need to be met is the time the CEO decides to approve the statement of participant supports; and
(b) a participant's disability support needs arising from an impairment in relation to which the participant meets the disability requirements or the early intervention requirements may be affected by a variety of factors, including environmental factors or the impact of another impairment in relation to which the participant does not meet either of those requirements.
(2) The National Disability Insurance Scheme rules may prescribe methods or criteria to be applied, or matters to which the CEO is to have regard, in deciding whether or not he or she is satisfied as mentioned in any of paragraphs (1)(aa) to (f).
Value for money > > 3.1 In deciding whether the support represents value for money in that the costs of the > > support are reasonable, relative to both the benefits achieved and the cost of alternative > > support, the CEO is to consider the following matters: > > (a) whether there are comparable supports which would achieve the same outcome at a substantially lower cost; > > (b) whether there is evidence that the support will substantially improve the life stage > > outcomes for, and be of long-term benefit to, the participant; > > (c) whether funding or provision of the support is likely to reduce the cost of the > > funding of supports for the participant in the long term (for example, some early > > intervention supports may be value for money given their potential to avoid or > > delay reliance on more costly supports); > > (d) for supports that involve the provision of equipment or modifications: > > (i) the comparative cost of purchasing or leasing the equipment or > > modifications; and > > (ii) whether there are any expected changes in technology or the participant's circumstances in the short term that would make it inappropriate to fund the equipment or modifications; > > (e) whether the cost of the support is comparable to the cost of supports of the same > > kind that are provided in the area in which the participant resides; > > (f) whether the support will increase the participant's independence and reduce the > > participant's need for other kinds of supports (for example, some home > > modifications may reduce a participant's need for home care). > > Effective and beneficial and current good practice > > 3.2 In deciding whether the support will be, or is likely to be, effective and beneficial for a > > participant, having regard to current good practice, the CEO is to consider the available > > evidence of the effectiveness of the support for others in like circumstances. That > > evidence may include: > > (a) published and refereed literature and any consensus of expert opinion; > > (b) the lived experience of the participant or their carers; or > > (c) anything the Agency has learnt through delivery of the NDIS. > > 3.3 In deciding whether the support will be, or is likely to be, effective and beneficial for a > > participant, having regard to current good practice, the CEO is to take into account, and if > > necessary seek, expert opinion. > > Reasonable family, carer and other support > > 3.4 In deciding whether funding or provision of the support takes account of what it is > > reasonable to expect families, carers, informal networks and the community to provide, > > the CEO is to consider the following matters: > > (a) for a participant who is a child: > > (i) that it is normal for parents to provide substantial care and support for > > children; and > > (ii) whether, because of the child's disability, the child's care needs are > > substantially greater than those of other children of a similar age; and > > (iii) the extent of any risks to the wellbeing of the participant's family members or carer or carers; and > > (iv) whether the funding or provision of the support for a family would improve the child's capacity or future capacity, or would reduce any risk to the child's wellbeing;
(c) standard home security and maintenance costs, fencing, gates, and building repairs;
(a) Funding for 24/7 support worker assistance at a: > > > (i) 2:1 rate Monday to Friday during school term (excluding school hours); > > > > (ii) 2:1 rate each weekend; and > > > > (iii) 1:1 active overnight 7 days per week (allowing for one parent to also provide active overnight support and the other to sleep). > > (b) One hour each way funding for support workers travel time to and from shifts (in addition to the kilometre allowance currently funded); > > (c) Home modifications consisting of: > > > (i) Installation of diplomat fencing; > > > > (ii) Internal modifications: > > > > (ii) a) bathroom, toilet and laundry modifications; > > > > (ii) b) bedroom, living and kitchen modifications; and > > > > (ii) c) perspex screen in front of television; and > > > > (ii) d) security locks for all external windows and doors.
.. significant progress during this intensive [NAPA] block, however, when returning home, follow through and continuing with recommended intervention has been almost impossible due to the complex needs and dynamic of the family. [The Applicant]'s parents are often trying to diffuse behaviour and situations of concern such as [the Applicant] absconding, turning taps on, pulling plumbing out etc, daughters fighting and becoming physical toward them and each other, and trying to maintain their home and farm (caring for livestock) that they do not have the capacity to offer the additional level of support required to implement therapy activities at home. This is why additional funding for support workers, and therapy is required. > > (Emphasis added)
I think the NAPA Centre is successful for [the Applicant] because he does have access to that high repetition of activities. He's in an environment that he feels safe in. [The Applicant] often likes to be in an environment where he feels like he can't leave. So having something like a lockable door there was. Yeah. So the environment, as well as having the two to one support. And then I guess when he's returning home, he's still got that two to one support in environment where there's a decrease in demands or other external factors like his siblings.
...is getting to the stage where [the mother] has voiced that she feels like she can no longer support [the Applicant] in a successful manner. And take I know this case is about [the Applicant], but it is imperative to take into consideration the two siblings because it is challenging for them not to intervene also. But regardless of them being in the picture or not in the picture, [the Applicant] still needs that two on one to be to be redirected. > > (Emphasis added).
severe, manifesting as very high levels of impulsivity, distractibility, and hyperactivity, predominantly for greater than 90% of the assessment period...Maladaptive coping strategies were more heavily impaired by ADHD traits than ASD...Free play was characterised by continuous sensory seeking behaviours, which transformed into goal-focused behaviour once suitable sensory stimuli (eg water play and light fittings) had been located for more in-depth engagement. > > ...
[The Applicant] has been trialled on medication and [the mother] has reported that for approximately 4 hours of the day, [the Applicant]'s behaviours were somewhat more manageable, however, after the 4 hour period, [the Applicant]'s behaviours escalated. Due to the complex nature of [the Applicant]'s multiple diagnoses at this time, medication is not deemed as a suitable treatment option.
If the clinical recommendations from all disciplines are not included in [the Applicant]'s new plan, his behaviours will continue to escalate, he will continue to regress across all domains of daily living, the financial burden for future services and long term intensive support will continue to increase, the physical and mental well being of all family members will be at significant risk of deterioration and exacerbation, and there is a very real possibility of [the Applicant] being placed in out of home care...
[The Applicant]: cease Vyvanse > > Risperidone (1mg/ml) 0.25ml at night for 1 week; > > If no improvement during day increase Risperidone 0.25ml a twice daily > > After 2 weeks if > > 1. persistent day time issues; increase morning dose to Risperidone 0.3ml; then may increase by 0.1ml every 2 wks to a maximum of 0.7ml in the am > > 2. persistent nighttime issues; increase night dose to Risperidone 0.3ml; then may increase by 0.1ml every 2 wks to a maximum of 0.7ml in the pm > > 3. this means for now max daily dose is 1.5ml per day (i.e 0.75ml twice daily)
There are two major barriers to [the Applicant] performing the tasks of daily living independently. > > The first is his profound autism which widely affects his cognition, communication and social skills. The second is his severe and untreated ADHD. If this were satisfactorily managed, a large extent of the burden of care would be removed. In some ways I would list this as an environmental barrier. I fully understand the challenges with transporting [the Applicant] long distances to see a specialist paediatrician or child psychiatrist, however in my experience almost all children with [the Applicant]'s presentation will benefit dramatically from medication for their ADHD. It is often the case that there are side effects, particularly early on, and that several different medications or dosing regimens need to be trialled, but I would expect that he would have major improvements in his hyperactivity and impulsivity which are so dominating the household and his whole life experience. > > I fully recognise that I have a limited understanding of [the Applicant]'s history and there may be some important item of medical information which has not been included in the documents, however it is distressing to see the amount of effort and heartache involved with [the Applicant]'s care that may be significantly ameliorated with medication for the ADHD.
It was very clear to me when I provided the initial report that all parties involved with his care agreed that [the Applicant]'s behaviour was dangerous and concerning, I formed an impression that two likely reasons why the utilised approaches were unsuccessful related to his untreated and severe ADHD as well as the difficult home situation with siblings requiring assistance through the NDIS and being remote from regular services.
There is once again a significant amount of provided information which would support [the Applicant] requiring 2 to 1 support to ensure his own safety, the safety of other people, and to assist him in activities of daily living. However, before providing my specific answer to this question, I would like to mention some important new information provided in the supplementary reports. > > Carefully reading through the carer impact statement by Crystal Luobikis dated September of 2024 it initially states that [the Applicant] requires 2 carers with him at all times due to his unpredictable nature and high needs. It then states that his two sisters both need one to one care themselves. After providing some discussion on the difficulties both sisters exhibit, the impact statement then intimates that having 2 to 1 carers for [the Applicant] would also assist with extra hands for the siblings. It states that both [the Applicant] and his sister need solid 1 to 1 support from the moment they wake up till when they go to sleep. > > ... > > It is therefore extremely difficult to advise regarding the need for two persons to support [the Applicant], and how often this is necessary. It sounds as though once or twice a day for a period of a couple of minutes that two people would be extremely beneficial, for the rest of the time they would be excessive to needs, and that potentially they are increasing [the Applicant]'s dependence upon others and lack of feeling of independence and ability to make decisions in life. Once again, I further consider that providing a safe environment including the desired fencing modifications along with management of the ADHD may obviate the need for a higher level of carer support.
...I am not going to recommend increased support worker hours at this point in time, this is not because I don't believe the multiple and cohesive information provided to me by the family and support workers. My recommendation is for strong consideration of treatment of severe ADHD and funding for a new fencing system around the house. I believe these two approaches are the most likely to make a difference for [the Applicant] and to help him with his long term independence and functioning. I would certainly reconsider my recommendations if his challenges and behaviour were not improved by those twin approaches.
However, I believe that medication trials for ADHD and other mental health diagnoses in [the Applicant] have so far been limited. I note he has trialled Fluoxetine which seemed to trigger him, which is predictable in a highly active child and there are other anti-anxiety, anti- OCD or antidepressant medications which are much less likely to cause such activation. Similarly, it appears that he has only trialled short and long acting forms of Dexamphetamine and not ever utilised Methylphenidate, Guanfacine or Atomoxetine all of which would be worth consideration. Guanfacine in particular is often extremely helpful for children with sleeping difficulties and for emotional regulation problems more than focus.
2021 - Clonidine > > No noticeable benefit > > Trial coincided with hallucinations and suspected seizures > > 2022 - Fluoxetine (SSRI) > > Trialled at 1/8th of a tablet for 7 days > > Caused severe headaches, anger, emotional distress, and verbal expressions of extreme pain > > Behaviour became highly agitated and aggressive, which is not his usual presentation > > Discontinued due to severe adverse effects > > 2022 - Dexamphetamine (Stimulant) > > Worked briefly for focus > > Caused severe OCD escalation, unmanageable manic behaviour, property damage, and increased aggression > > Discontinued due to safety risks > > 2022 to Present - Risperidone (Used Occasionally) > > Reserved for extreme episodes or suspected psychotic features > > Occasional calming effect > > Worsens ADHD-related impulsivity > > Not suitable for consistent management > > 2024 - Vyvanse (Stimulant) > > Temporary benefit followed by major behavioural crashes > > Triggered severe OCD episodes, increased absconding, manic episodes, and significantly disrupted sleep > > Overall made behaviour worse than when unmedicated > > ... > > We have trialled all recommended medications, and every single one has either worsened [the Applicant]'s symptoms or produced severe side effects.
More information will be ascertained ongoing to understand how sleeping links to behaviours. [the Applicant]'s last paediatrician appointment occurred early July 2024, which resulted in no changes or medication aside from a prescription for antibiotics and Terbinafine to treat an ongoing fungal infection on his foot. [The Applicant] was previously prescribed Risperidone, Fluoxetine and Dexamphetamines; however, all three medications were reported to produce adverse side effects including negative changes in overall affect and frequent headaches. [The Applicant] is reported to be "thriving" without the use of medication, although [The Applicant's mother] is interested in exploring OCD specific medication in the future should there be changes to his overall state of regulation. [The Applicant] is also reported to experience seizure activity, with a diagnosis of Epilepsy including Gelastic, Partial Focal and Absent seizures. More information regarding [the Applicant]'s physical health, particularly his sleep and seizure activity, will be ascertained in the ongoing discussions with the family. [The Applicant's mother] has expressed to the BSP some concern around placing [the Applicant] on any medications due to previous poor experiences associated with negative side effects, however, is open to speaking with a medical professional around future support, particuarly (sic) in relation to seizure activity and OCD.
...medicating somebody is not the answer to a behaviour of concern.
When we medicate someone it doesn't necessarily meet that person's needs, we're not honouring their communication and in my opinion we're not allowing for that holistic approach. That is really the crux of when we're looking at person centred planning and ethical practice.
[201] The matters set out in s 34(1) are more than mandatory considerations, because in terms s 34 requires that a decision-maker be positively satisfied about each matter. They are more in the nature of criteria of which the decisions-maker (CEO, delegate or Tribunal) must be satisfied on the material. That satisfaction must be reasonably and rationally formed, not taking into account irrelevant considerations, and taking into account any relevant considerations, but otherwise it is for the decision-maker to form the requisite state of satisfaction on the given material.
And so unfortunately in our case meetings and conversations, we have had to put all the options on the board because if we are not funded appropriately, what other options are we looking at?
a) Providers of daily activity and community participation supports can claim travel costs when travelling to appointments in some circumstances.
b) Providers may not claim travel costs for the time that a support worker spends travelling from home to their workplace (or first participant) and from the workplace (or last participant) to home.
c) Where a support worker travels from one participant appointment to another, up to 30 minutes of time can be claimed against the next appointment at the hourly rate for the relevant support item.
d) Where a worker travels from one participant appointment to another in an MMM 4 or MMM 5 area, up to 60 minutes of time can be claimed against the next appointment at the hourly rate for the relevant support item.
Provider Travel > > Providers can only claim travel costs from a participant's plan when delivering a support item if all the following conditions are met:
Provider Travel - Labour Costs (Time) > > The NDIA uses the Modified Monash Model (MMM) to classify locations based on remoteness and population size, categorising them into MMM1 (major cities) to MMM7 (very remote areas). The NDIA modifies the classification of some locations to enable service delivery in isolated areas to support service delivery. > > When a provider claims for labour costs (travel time) related to a support, they can claim for up to 30 minutes of travel to and from each participant in MMM1-3 areas and up to 60 minutes in MMM4 5 areas for each eligible worker. This is known as a travel time limit. The MMM classification is based on where the participant is when the support is delivered. More information can be found on page 30. > > In addition to the above travel, providers delivering core and capacity-building supports can also claim for travel time from the last participant to their usual place of work but only if they must pay their worker for the return travel time and this is subject to the relevant travel time limit. > > If a worker travels to provide services to multiple participants during the same trip, the travel time (including return travel where applicable) can be divided among the participants. This division should be agreed upon with each participant in advance as part of their Service Agreement. Travel time claims must be made separately from the primary support claim using the same line item and the "Provider Travel" option in the myplace Provider Portal. The hourly rate for travel claims should be the same as the rate agreed for the primary support, or lower if agreed with the participant. > > ... > > Provider Travel - Non-Labour Costs > > If a provider incurs costs, in addition to the cost of a worker's time, when travelling to deliver Face to-Face supports to a participant (such as road tolls, parking fees and the running costs of the vehicle), they may negotiate with the participant for them to make a reasonable contribution towards these costs. The NDIA considers that the following would be reasonable contributions:
Claims can only be made for the non-labour costs associated with provider travel in respect of a support where the rules governing provider travel allow a claim for provider travel time to be made. > > Claims for the non-labour costs of provider travel in respect of a support must be made separately to the claim for the primary support (the support for which the travel is necessary) and for the travel time associated with the provider travel. The non-labour costs should be claimed against the relevant "Provider Travel - non-labour costs" support item as indicated in the NDIS Pricing Arrangements and Price Limits.
(e) standard home repairs, home improvements, standard renovations and maintenance;
The CEO may determine, in writing, that a support is taken to not be declared under subsection (4) in relation to a participant if:
(a) the support is prescribed by the National Disability Insurance Scheme rules for the purposes of this paragraph; and
(b) the support would, apart from subsection (4), be an NDIS support for the participant; and
(c) the participant applies to the CEO in accordance with subsection (7) for the determination; and
(i) the support would replace one or more other supports that are NDIS supports for the participant; and
(ii) the cost of the support is the same or lower than the total of the costs of the supports it would replace; and
(iii) the support would provide the same or a better outcome for the participant than the supports it would replace; and
(iv) any other conditions specified in the National Disability Insurance Scheme rules for the purposes of this subparagraph are met in relation to the support, the participant, or both.
Pursuant to section 105(c) of the Administrative Review Tribunal Act 2024 the decision under review made pursuant to section 48 of the National Disability Insurance Scheme Act 2013 on 29 May 2025 is set aside and remitted to the CEO for reconsideration in accordance with the order that:
(1) The following supports are reasonable and necessary supports pursuant to subsection 34(1) of the National Disability Insurance Scheme Act 2013:
(a) six hours per day of assistance with daily life at a ratio of 1:1 at the standard intensity pricing for 48 weeks per annum;
(b) two hours of social, community and civic participation at a ratio of 1:1 at the Saturday rate and the Sunday rate for 48 weeks per annum;
(2) All other reasonable and necessary supports in the Applicant's current statement of participant supports shall be replicated;
(3) The reassessment date is 12 months after the day on which the above reasonable and necessary supports are included in the Applicant's statement of participant supports; and
(4) In accordance with section 101(a) of the Administrative Review Tribunal Act 2024 the application for review insofar as it concerns the internal review decision dated 23 August 2023 and the decisions to approve a statement of participant supports on 25 January 2024, 24 April 2024 and 30 October 2024 are dismissed on the basis that they are lacking in substance.
Mr William Robin, Multicultural Disability Advocacy Association
Mses Dantu-Hann and Law, Moray and Agnew Lawyers
[3] This proceeding commenced before the Administrative Appeals Tribunal (AAT) in accordance with the power conferred by s 25 of the Administrative Appeals Tribunals Tribunal Act 1975 (Cth). The AAT was abolished and replaced by the Administrative Review Tribunal (ART) with effect from 14 October 2024. By operation of Item 24 in Schedule 16 of the Administrative Review Tribunal (Consequential and Transitional Provisions No 1) Act 2024 (Cth) any proceeding which was not determined by 14 October 2024 continues in the ART and is to be determined by the application of the provisions of the ART Act.
G v Minister for Immigration and Border Protection [2018] FCA 1229
National Disability Insurance Agency v WRMF [2020] FCAFC 79
National Disability Insurance Agency v Deayton [2025] FCA 562